Our Expert Network

  1. Tracking 4 Payload Trends In Drug Delivery Development 1/22/2024

    Amid new research and development in nanocarriers, market attention has shifted toward payloads and enhancing compatibility. This discussion explores the latest trends and includes a research database.

  2. Surmounting The Challenges To Realizing The Potential Of CGT For Neurological Disorders 1/18/2024

    Incorporating innovative technologies, such as CRISPR/Cas9, and understanding the molecular basis of neurological disorders are crucial in shaping the future of gene therapy.

  3. Oligonucleotides Outsourcing In 2024 1/9/2024

    2023, among other potential designations, was the year of oligonucleotides. Accordingly, here’s a question I raised with professionals throughout the year: How do you successfully outsource development and manufacture of an oligo program?

  4. Cell & Gene Therapies: How Can Our Knowledge Of 2023 Inform Our Predictions For 2024? 1/8/2024

    2024 promises a potential turnaround and blue skies for cell and gene therapies. Let’s explore each modality’s prospects: oligos and mRNA, cell therapies, and viral gene therapies.

  5. A Look At siRNA & Market Trends 1/3/2024

    Small interfering RNA (siRNA) is a class of molecules that play a crucial role in the regulation of gene expression. This article shares how siRNA functions as well as new market research for the field.

  6. RNA Vaccines: Just Scratching The Surface 12/28/2023

    RNA vaccines have shown promise in preventing infectious diseases and treating cancer, but clinical development varies markedly between the two. HDT Bio’s Dr. Berglund discusses this and how they can be improved.

  7. Understanding FDA's Rare Disease Therapeutics Pilot Program 12/18/2023

    FDA aims to advance medical research and therapeutic solutions for rare diseases with its Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program. 

  8. Understanding CQAs For mRNA/Lipid Nanoparticle Product Development And Manufacture 12/13/2023

    BioPhorum recently created a resource of potential critical quality attributes (CQAs) for mRNA products from the early stages of drug development to commercial manufacturing. We asked two of the paper’s authors some questions to explore the key areas in more detail.

  9. 5 Leadership Learnings In Preventative Cancer Vaccine Development 12/6/2023

    Calviri has been developing an RNA vaccine to prevent cancer for more than 20 years and repeatedly faced the nearly universal belief that it’s impossible. We’ve learned a number of important lessons along the way that are worth imparting to other vaccine developers.

  10. The RNA Therapeutics Race: How Can Pharma Stay Ahead Of The Wave? 12/5/2023

    With more than 970 RNA therapies currently in the development pipeline, the market presents an exciting prospect. This article shares the key attributes of RNA therapies that are paving the way for personalized medicine, novel delivery mechanisms, and more.